Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Rises By 16.6%

Biofrontera Inc. (NASDAQ:BFRIGet Rating) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 993,900 shares, a growth of 16.6% from the March 31st total of 852,200 shares. Currently, 12.4% of the company’s stock are short sold. Based on an average daily volume of 2,790,000 shares, the short-interest ratio is presently 0.4 days.

BFRI stock opened at $3.76 on Wednesday. The firm’s 50-day moving average price is $3.34. Biofrontera has a 12-month low of $2.20 and a 12-month high of $14.63.

Biofrontera (NASDAQ:BFRIGet Rating) last announced its quarterly earnings data on Friday, April 8th. The company reported ($0.42) earnings per share (EPS) for the quarter. The business had revenue of $9.17 million during the quarter. As a group, equities research analysts forecast that Biofrontera will post -0.72 EPS for the current year.

Separately, Zacks Investment Research lowered Biofrontera from a “buy” rating to a “hold” rating in a research report on Tuesday, March 15th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP bought a new position in Biofrontera during the fourth quarter valued at about $384,000. Geode Capital Management LLC acquired a new stake in Biofrontera during the fourth quarter valued at approximately $182,000. Qube Research & Technologies Ltd bought a new position in shares of Biofrontera in the fourth quarter valued at approximately $103,000. Finally, BlackRock Inc. bought a new position in Biofrontera in the 4th quarter worth approximately $76,000. Institutional investors own 4.10% of the company’s stock.

Biofrontera Company Profile (Get Rating)

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.

Featured Articles

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with's FREE daily email newsletter.